Clinical Scorecard: Initial Biopsychological Transformations in AFAB Transgender Individuals Undergoing Masculinizing Hormone Therapy: A 4-Month Prospective Investigation

At a Glance

Key Highlights

• Significant reductions in anxiety and trauma-related symptoms observed after 4 months of therapy.
• Improvements in quality of life measures over time.
• Endocrine changes included decreased estradiol and increased testosterone levels.
• Associations between hormonal changes and psychological outcomes were more pronounced after 4 months.
• Psychological improvements were influenced by psychosocial and treatment-related factors.

Guideline-Based Recommendations

Diagnosis

• Participants met clinical diagnostic criteria for gender dysphoria.

Management

• Initiation of masculinizing hormone therapy as indicated for individuals with gender dysphoria.

Monitoring & Follow-up

• Regular assessments of hormonal parameters and psychological measures at baseline, 2 months, and 4 months.

Risks

• Potential psychological distress associated with gender dysphoria and treatment initiation.

Patient & Prescribing Data

30 transgender individuals assigned female at birth, aged 18 years or older.

No previous hormonal treatments or surgeries prior to the study; no significant non-adherence to therapy.

Clinical Best Practices

• Conduct longitudinal assessments to monitor both endocrine and psychological changes.
• Utilize validated psychometric instruments for psychological evaluation.
• Consider psychosocial factors in treatment planning and support.

Related Resources & Content

• Study on psychological distress in transgender individuals
• Effects of testosterone on emotional processing
• Minority stress theory and mental health disparities